Cannabigerol Market

Cannabigerol Market Forecast and Outlook 2025 to 2035

The global cannabigerol market is projected to grow from USD 890.0 million in 2025 to approximately USD 2,050.0 million by 2035, recording an absolute increase of USD 1,160.0 million over the forecast period. This translates into a total growth of 130.3%, with the market forecast to expand at a compound annual growth rate (CAGR) of 8.7% between 2025 and 2035.

The overall market size is expected to grow by nearly 2.3X during the same period, supported by increasing demand for natural therapeutic compounds, rising adoption of cannabis-derived ingredients, and growing focus on alternative medicine solutions across the global pharmaceutical and nutraceutical sectors.

The market represents one of the most rapidly expanding segments within the broader cannabinoid industry, driven by groundbreaking research discoveries and evolving regulatory frameworks that recognize the therapeutic potential of minor cannabinoids. Often referred to as the "mother of all cannabinoids," CBG serves as the precursor compound from which other major cannabinoids like CBD and THC are biosynthesized, making it a particularly valuable and scientifically significant component of the cannabis plant. This unique positioning, combined with emerging clinical evidence supporting CBG's distinctive therapeutic properties, has positioned the compound at the forefront of pharmaceutical innovation and nutraceutical development.

The market dynamics propelling CBG adoption are fundamentally different from those driving traditional cannabis products, reflecting a sophisticated understanding of cannabinoid science and therapeutic applications. Unlike CBD, which has achieved mainstream acceptance primarily through consumer wellness products, CBG is gaining traction through targeted pharmaceutical research and specialized medical applications. Scientific studies have identified CBG's potential efficacy in treating inflammatory bowel disease, glaucoma, Huntington's disease, and various bacterial infections, creating substantial interest from pharmaceutical companies seeking novel therapeutic compounds with well-defined mechanisms of action.

The regulatory landscape surrounding CBG continues to evolve favorably, with many jurisdictions treating hemp-derived CBG similarly to CBD under existing legal frameworks. This regulatory clarity has enabled significant investment in specialized cultivation, extraction, and purification technologies designed specifically for CBG production. The compound's low natural occurrence in cannabis plants—typically less than 1% of total cannabinoid content—has driven innovation in plant breeding, genetic modification, and optimized extraction methods to achieve commercial viability and scalability.

Manufacturing complexity represents both a challenge and opportunity within the CBG market. The compound's instability and tendency to convert to other cannabinoids during cultivation requires sophisticated timing and processing techniques, creating barriers to entry that benefit established players with advanced technical capabilities. This technical complexity has led to premium pricing structures and specialized supply chain relationships, differentiating the CBG market from more commoditized cannabinoid segments.

Quick Stats for Cannabigerol Market

• Cannabigerol Market Value (2025): USD 890.0 million
• Cannabigerol Market Forecast Value (2035): USD 2,050.0 million
• Cannabigerol Market Forecast CAGR: 8.7%
• Leading Source in Cannabigerol Market: Hemp (85.0%)
• Key Growth Regions in Cannabigerol Market: Asia Pacific, North America, and Europe
• Key Players in Cannabigerol Market: EcoGen Biosciences, Gencanna, KND Labs, Mile High Labs, Cannabinoid Creations, Folium Biosciences, Creo, Open Book Extracts, Front Range Biosciences

Between 2025 and 2030, the cannabigerol market is projected to expand from USD 890.0 million to USD 1,390.0 million, resulting in a value increase of USD 500.0 million, which represents 43.1% of the total forecast growth for the decade.

This phase of development will be shaped by rising demand for natural therapeutic compounds, increasing applications in pharmaceutical research and wellness products, and growing penetration in emerging healthcare markets.

Cannabis processing companies are expanding their production capabilities to address the growing demand for high-quality CBG extracts in various therapeutic segments and wellness programs.

Cannabigerol Market Key Takeaways

Metric	Value
Estimated Value in (2025E)	USD 890.0 million
Forecast Value in (2035F)	USD 2,050.0 million
Forecast CAGR (2025 to 2035)	8.7%

From 2030 to 2035, the market is forecast to grow from USD 1,390.0 million to USD 2,050.0 million, adding another USD 660.0 million, which constitutes 56.9% of the overall ten-year expansion.

This period is expected to be characterized by the expansion of advanced extraction technologies, the integration of cutting-edge cannabinoid research, and the development of specialized CBG formulations for specific therapeutic applications.

The growing adoption of personalized medicine approaches and evidence-based wellness solutions will drive demand for ultra-pure CBG products with enhanced bioavailability specifications and consistent therapeutic characteristics.

Between 2020 and 2025, the cannabigerol market experienced rapid expansion, driven by increasing recognition of cannabinoid compounds' importance in therapeutic applications and growing acceptance of hemp-derived products in regulated healthcare markets.

The market developed as pharmaceutical companies recognized the need for novel therapeutic compounds to address complex health conditions and improve overall treatment outcomes.

Research and development activities have begun to emphasize the importance of minor cannabinoids in achieving better therapeutic efficacy and performance in various medical applications.

Why is the Cannabigerol Market Growing?

Market expansion is being supported by the increasing demand for natural therapeutic alternatives and the corresponding need for high-efficacy cannabinoid compounds in pharmaceutical applications across global healthcare and wellness operations.

Modern pharmaceutical companies are increasingly focused on advanced cannabinoid research that can improve treatment outcomes, reduce side effects, and enhance therapeutic performance while meeting stringent regulatory requirements. The proven efficacy of CBG in various therapeutic applications makes it an essential component of comprehensive treatment strategies and drug development programs.

The growing emphasis on personalized medicine and advanced therapeutic optimization is driving demand for ultra-pure cannabinoid compounds that meet stringent quality specifications and regulatory requirements for specialized applications.

Healthcare providers' preference for reliable, high-performance therapeutic compounds that can ensure consistent treatment outcomes is creating opportunities for innovative cannabinoid technologies and customized pharmaceutical solutions.

The rising influence of evidence-based medicine protocols and regulatory approval standards is also contributing to increased adoption of premium-grade CBG products across different therapeutic applications and wellness systems requiring advanced therapeutic technology.

Opportunity Pathways - Cannabigerol Market

The cannabigerol market represents a specialized growth opportunity, expanding from USD 890.0 million in 2025 to USD 2,050.0 million by 2035 at an 8.7% CAGR. As healthcare providers prioritize treatment efficacy, therapeutic innovation, and patient outcomes in complex medical processes, CBG has evolved from a niche cannabinoid research area to an essential component enabling pharmaceutical development, therapeutic optimization, and multi-stage medical production across healthcare operations and specialized therapeutic applications.

The convergence of pharmaceutical expansion, increasing research adoption, specialized healthcare infrastructure growth, and regulatory requirements creates momentum in demand. High-purity formulations offering superior therapeutic performance, cost-effective hemp-derived systems balancing efficacy with economics, and specialized synthetic variants for pharmaceutical applications will capture market premiums, while geographic expansion into high-growth North American healthcare markets and emerging market penetration will drive volume leadership. Healthcare emphasis on efficacy and safety provides structural support.

• Pathway A - Hemp Source Dominance: Leading with 85.0% market share, hemp applications drive primary demand through complex extraction workflows requiring comprehensive processing systems for natural CBG production. Advanced formulations enabling improved therapeutic efficacy, reduced production costs, and enhanced purity performance command premium pricing from pharmaceutical companies requiring stringent quality specifications and regulatory compliance. Expected revenue pool: USD 756.5-1,742.5 million.
• Pathway B - Pharmaceutical Leadership: Dominating with 45.0% market share through an optimal balance of therapeutic efficacy and safety requirements, pharmaceutical applications serve most healthcare needs while meeting regulatory protection requirements. This application addresses both therapeutic standards and safety considerations, making it the preferred choice for healthcare and pharmaceutical operations seeking reliable treatment outcomes. Opportunity: USD 400.5-922.5 million.
• Pathway C - Asian Market Acceleration: China (9.0% CAGR) and South Korea (7.0% CAGR) lead regional growth through healthcare infrastructure expansion, pharmaceutical development, and domestic CBG demand. Strategic partnerships with local pharmaceutical companies, regulatory compliance expertise, and supply chain localization enable the expansion of cannabinoid technology in major healthcare hubs. Geographic expansion upside: USD 178.0-410.0 million.
• Pathway D - Isolate Premium Segment: Isolate applications serve specialized operations requiring exceptional purity specifications for critical therapeutic processes. Isolate formulations supporting complex pharmaceutical requirements, research applications, and performance-sensitive processes command significant premiums from advanced pharmaceutical organizations and specialized research facilities. Revenue potential: USD 534.0-1,230.0 million.
• Pathway E - Advanced Extraction & Processing Systems: Companies investing in sophisticated extraction technologies, automated purification systems, and intelligent processing processes gain competitive advantages through consistent product quality and therapeutic reliability. Advanced capabilities enabling customized specifications and rapid production capture premium pharmaceutical partnerships. Technology premium: USD 89.0-205.0 million.
• Pathway F - Supply Chain Optimization & Quality: Specialized distribution networks, strategic inventory management, and reliable supply chain systems create competitive differentiation in pharmaceutical markets requiring consistent CBG availability. Companies offering guaranteed supply security, technical support, and regulatory documentation gain preferred supplier status with healthcare-focused pharmaceutical companies. Supply chain value: USD 53.4-123.0 million.
• Pathway G - Emerging Applications & Market Development: Beyond traditional pharmaceutical uses, CBG in cosmetic applications, specialized wellness products, and novel therapeutic systems represent growth opportunities. Companies developing new applications, supporting R&D initiatives, and expanding into adjacent healthcare markets capture incremental demand while diversifying revenue streams. Emerging opportunity: USD 35.6-82.0 million.

Segmental Analysis

The market is segmented by source, application, form, and region. By source, the market is divided into hemp and synthetic. Based on application, the market is categorized into pharmaceuticals, nutraceuticals, cosmetics, and others. By form, the market is divided into isolate and full spectrum. Regionally, the market is divided into Asia Pacific, North America, Europe, Latin America, Middle East & Africa.

By Source, Hemp Segment Accounts for 85.0% Market Share

Hemp-sourced cannabigerol is projected to account for 85.0% of the market in 2025, reaffirming its position as the category's dominant source. Cannabis processors increasingly recognize the optimal balance of cost-effectiveness and quality offered by hemp-derived CBG for most commercial applications, particularly in pharmaceutical production and wellness products. This source addresses both regulatory requirements and economic considerations while providing reliable cannabinoid content across diverse therapeutic applications.

This source forms the foundation of most commercial protocols for CBG production, as it represents the most widely accepted and commercially viable level of cannabinoid extraction technology in the industry. Regulatory standards and extensive quality testing continue to strengthen confidence in hemp-derived CBG formulations among pharmaceutical and nutraceutical providers. With increasing recognition of the cost-quality optimization requirements in cannabinoid production, hemp systems align with both operational efficiency and therapeutic goals, making them the central growth driver of comprehensive pharmaceutical development strategies.

By Application, Pharmaceutical Segment Accounts for 45.0% Market Share

Pharmaceuticals are projected to represent 45.0% of cannabigerol demand in 2025, underscoring their role as the primary application segment driving market adoption and growth. Pharmaceutical companies recognize that drug development requirements, including complex therapeutic formulations, specialized treatment needs, and multi-stage research systems, often require advanced CBG compounds that standard wellness ingredients cannot adequately provide. CBG offers enhanced therapeutic potential and regulatory compliance in pharmaceutical drug development applications.

The segment is supported by the growing complexity of therapeutic research, requiring sophisticated cannabinoid compounds, and the increasing recognition that advanced cannabinoid technologies can improve pharmaceutical outcomes and treatment results. Additionally, pharmaceutical companies are increasingly adopting evidence-based development guidelines that recommend specific CBG applications for optimal therapeutic efficacy. As understanding of cannabinoid pharmacology advances and pharmaceutical requirements become more stringent, CBG will continue to play a crucial role in comprehensive drug development strategies within the pharmaceutical market.

By Form, Isolate Segment Accounts for 60.0% Market Share

Isolate applications are projected to represent 60.0% of cannabigerol demand in 2025, demonstrating their critical role as the primary form segment driving market expansion and adoption. Pharmaceutical operators recognize that isolate requirements, including complex purification processes, specialized quality standards, and precise dosing systems, often require advanced CBG isolates that standard full spectrum products cannot adequately provide. Isolate CBG offers enhanced purity control and regulatory compliance in pharmaceutical production applications.

What are the Drivers, Restraints, and Key Trends of the Cannabigerol Market?

The cannabigerol market is advancing steadily due to increasing recognition of minor cannabinoid technologies' importance and growing demand for high-efficacy therapeutic compounds across the pharmaceutical and wellness sectors.

However, the market faces challenges, including complex regulatory processes, potential for quality variations during extraction and processing, and concerns about supply chain consistency for specialized cannabinoid products. Innovation in extraction technologies and customized therapeutic protocols continues to influence product development and market expansion patterns.

Expansion of Advanced Research Facilities and Cannabinoid Technologies

The growing adoption of advanced research facilities is enabling the development of more sophisticated CBG production and quality control systems that can meet stringent pharmaceutical requirements.

Specialized research facilities offer comprehensive cannabinoid services, including advanced extraction and purification processes that are particularly important for achieving high-purity requirements in pharmaceutical applications.

Advanced research infrastructure provides access to premium services that can optimize therapeutic performance and reduce production costs while maintaining cost-effectiveness for large-scale pharmaceutical operations.

Integration of Pharmaceutical Standards and Quality Management Systems

Modern pharmaceutical organizations are incorporating regulatory technologies such as real-time quality monitoring, automated testing systems, and compliance integration to enhance CBG development and distribution processes.

These technologies improve product quality, enable continuous quality monitoring, and provide better coordination between manufacturers and pharmaceutical operators throughout the production cycle.

Advanced regulatory platforms also enable customized therapeutic specifications and early identification of potential quality deviations or supply disruptions, supporting reliable pharmaceutical production.

Analysis of the Cannabigerol Market by Key Country

Country	CAGR (2025-2035)
China	9.0%
USA	8.5%
Canada	8.0%
Germany	7.8%
UK	7.6%
South Korea	7.0%
Japan	6.8%

The cannabigerol market is experiencing varied growth globally, with China leading at a 9.0% CAGR through 2035, driven by the expansion of pharmaceutical infrastructure development, increasing research capacity capabilities, and growing domestic demand for high-quality cannabinoid compounds. USA follows at 8.5%, supported by regulatory advancement, growing recognition of cannabinoid therapy importance, and expanding pharmaceutical capacity. Canada records 8.0% growth, with a focus on developing the cannabis research and pharmaceutical industries.

Germany shows 7.8% growth, representing a leading European market with expanding pharmaceutical frameworks. UK demonstrates 7.6% growth with focus on advanced pharmaceutical adoption. South Korea demonstrates 7.0% growth, emphasizing pharmaceutical infrastructure expansion and systematic research approaches. Japan demonstrates 6.8% growth, emphasizing healthcare infrastructure expansion and systematic pharmaceutical approaches.

China Demonstrates Growing Market Potential with Pharmaceutical Infrastructure Development

Revenue from cannabigerol in China is projected to exhibit robust growth with a CAGR of 9.0% through 2035, driven by ongoing pharmaceutical expansion and increasing recognition of high-quality cannabinoid compounds as essential therapeutic components for complex medical processes. The country's expanding healthcare infrastructure and growing availability of specialized research capabilities are creating significant opportunities for CBG adoption across both domestic and export-oriented pharmaceutical facilities. Major international and domestic pharmaceutical companies are establishing comprehensive research and development networks to serve the growing population of healthcare providers and pharmaceutical facilities requiring high-performance cannabinoid compounds across therapeutic and research applications throughout China's major pharmaceutical hubs.

The Chinese government's strategic emphasis on pharmaceutical modernization and healthcare advancement is driving substantial investments in specialized research capabilities. This policy support, combined with the country's large domestic pharmaceutical market and expanding healthcare requirements, creates a favorable environment for the CBG market development. Chinese pharmaceutical companies are increasingly focusing on high-value therapeutic technologies to improve healthcare capabilities, with CBG representing a key component in this pharmaceutical transformation.

• Government initiatives supporting pharmaceutical development and healthcare modernization are driving demand for high-quality cannabinoid compounds throughout major pharmaceutical and research centers, including Beijing, Shanghai, and Guangzhou regions.
• Pharmaceutical capacity expansion and research system development are supporting appropriate utilization of CBG among pharmaceutical companies and research facilities nationwide, with particular growth in drug development operations and pharmaceutical research services.

USA Demonstrates Exceptional Market Potential with Regulatory Growth

Revenue from cannabigerol in USA is expanding at a CAGR of 8.5%, supported by increasing regulatory accessibility, growing pharmaceutical awareness, and developing research market presence across the country's major pharmaceutical clusters. The country's large healthcare sector and increasing recognition of advanced cannabinoid compounds are driving demand for effective high-quality therapeutic solutions in both pharmaceutical development and healthcare applications. International pharmaceutical companies and domestic providers are establishing comprehensive distribution channels to serve the growing demand for quality cannabinoid compounds while supporting the country's position as a leading pharmaceutical technology market.

USA's pharmaceutical sector continues to benefit from favorable regulatory policies, expanding research capabilities, and cost-competitive pharmaceutical infrastructure development. The country's focus on becoming a global pharmaceutical technology leader is driving investments in specialized cannabinoid technology and therapeutic management infrastructure. This development is particularly important for CBG applications, as pharmaceutical companies seek reliable domestic sources for critical therapeutic technologies to reduce import dependency and improve supply chain security.

• Rising awareness about advanced therapeutic options and improving pharmaceutical capabilities are creating opportunities for specialized cannabinoid compounds across pharmaceutical and healthcare settings in major hubs like New York, California, and Massachusetts.
• Growing pharmaceutical infrastructure development and technology adoption are supporting increased access to high-quality CBG among organizations requiring comprehensive therapeutic capabilities, particularly in pharmaceutical development and healthcare organizations.

Canada Maintains Research Leadership

Canada's advanced pharmaceutical technology market demonstrates sophisticated healthcare infrastructure deployment with documented CBG effectiveness in pharmaceutical departments and research centers through integration with existing healthcare systems and regulatory infrastructure. The country leverages pharmaceutical expertise in cannabinoid technology and therapeutic systems integration to maintain an 8.0% CAGR through 2035. Research centers, including major metropolitan areas, showcase premium installations where CBG integrates with comprehensive pharmaceutical information systems and regulatory platforms to optimize therapeutic accuracy and operational workflow effectiveness.

Canadian pharmaceutical companies prioritize product quality and regulatory compliance in development processes, creating demand for premium compounds with advanced features, including performance validation and integration with Canadian pharmaceutical standards. The market benefits from established pharmaceutical industry infrastructure and a willingness to invest in advanced cannabinoid technologies that provide long-term therapeutic benefits and compliance with healthcare regulations.

Germany Shows Strong Regional Leadership

Germany's market expansion benefits from diverse pharmaceutical demand, including healthcare infrastructure modernization in Berlin and Munich, research development programs, and government pharmaceutical programs that increasingly incorporate CBG solutions for therapeutic enhancement applications. The country maintains a 7.8% CAGR through 2035, driven by rising pharmaceutical awareness and increasing adoption of therapeutic benefits, including superior quality capabilities and reduced complexity.

Market dynamics focus on cost-effective cannabinoid solutions that balance advanced therapeutic features with affordability considerations important to German pharmaceutical operators. Growing pharmaceutical infrastructure creates demand for modern cannabinoid compounds in new research facilities and pharmaceutical equipment modernization projects.

Strategic Market Considerations:

• Pharmaceutical and healthcare infrastructure segments leading growth with focus on therapeutic enhancement and research efficiency applications
• Regional pharmaceutical requirements are driving a diverse product portfolio from basic cannabinoid compounds to advanced therapeutic platforms
• Import dependency challenges offset by potential local development partnerships with international pharmaceutical manufacturers
• Government healthcare initiatives beginning to influence procurement standards and pharmaceutical infrastructure requirements

UK Emphasizes Advanced Pharmaceutical Development

UK demonstrates strong market development with a 7.6% CAGR through 2035, driven by advanced pharmaceutical infrastructure and healthcare preference for technology-integrated CBG products. The country's sophisticated healthcare ecosystem and high research adoption rates are creating significant opportunities for CBG adoption across both domestic and technology-driven pharmaceutical facilities. Based on the provided split data, UK's application breakdown shows Pharmaceuticals at 45.0%, Nutraceuticals at 35.0%, and Cosmetics at 20.0%, reflecting the country's diversified healthcare base and strong focus on pharmaceutical infrastructure development.

British pharmaceutical companies are increasingly incorporating CBG into drug development pipelines, particularly for neurological and inflammatory conditions. The market is supported by favorable government policies promoting medical cannabis research and the presence of world-class universities conducting cannabinoid studies. Supply chain optimization and regulatory compliance remain key competitive factors, with companies establishing comprehensive quality management systems to serve both domestic pharmaceutical markets and international export opportunities across European Union countries.

South Korea Shows Steady Market Growth

South Korea demonstrates steady market development with a 7.0% CAGR through 2035, distinguished by pharmaceutical operators' preference for high-quality cannabinoid compounds that integrate seamlessly with existing healthcare equipment and provide reliable long-term operation in specialized pharmaceutical applications. The market prioritizes advanced features, including precision extraction algorithms, quality validation, and integration with comprehensive pharmaceutical platforms that reflect Korean healthcare expectations for technological advancement and operational excellence.

Strategic Market Indicators:

• Premium focus on precision compounds with advanced therapeutic algorithms and high-reliability capabilities for pharmaceutical applications requiring exceptional performance standards
• Integration requirements with existing pharmaceutical information systems and healthcare management platforms supporting comprehensive medical automation
• Emphasis on CBG reliability and long-term performance in pharmaceutical applications with strict operational requirements
• Strong preference for locally manufactured compounds that comply with Korean healthcare standards and regulatory requirements

Japan Emphasizes Precision and Integration Excellence

Japan demonstrates steady market development with a 6.8% CAGR through 2035, distinguished by healthcare operators' preference for high-quality cannabinoid compounds that integrate seamlessly with existing pharmaceutical equipment and provide reliable long-term operation in specialized healthcare applications. Based on the provided split data, Japan's source breakdown shows Hemp at 90.0% and Synthetic at 10.0%, indicating a strong preference for natural extraction while maintaining flexibility for pharmaceutical-grade synthetic production needs. The market prioritizes advanced features, including precision extraction algorithms, quality validation, and integration with comprehensive healthcare platforms that reflect Japanese pharmaceutical expectations for technological advancement and operational excellence.

The regulatory environment in Japan supports controlled cannabinoid research while maintaining strict quality standards that drive demand for premium-grade CBG products. Japanese healthcare providers increasingly recognize the therapeutic potential of minor cannabinoids, particularly in addressing aging population health challenges. Strategic partnerships between international CBG suppliers and local pharmaceutical distributors facilitate market access, with emphasis on meeting Japanese pharmaceutical standards and providing comprehensive technical support for healthcare applications requiring exceptional reliability and performance consistency.

Europe Market Split by Country

The cannabigerol market in Europe is projected to grow significantly, with individual country performance varying across the region. Germany is expected to maintain its leadership position with a market value of USD 200.0 million in 2025, supported by its advanced pharmaceutical infrastructure, precision healthcare management capabilities, and strong research presence throughout major pharmaceutical regions.

UK follows with USD 150.0 million in 2025, driven by advanced regulatory protocols, pharmaceutical innovation integration, and expanding research networks serving both domestic and international markets. France holds USD 120.0 million in 2025, supported by pharmaceutical infrastructure expansion and growing adoption of high-quality cannabinoid compounds. Italy commands USD 100.0 million in 2025, while Spain accounts for USD 80.0 million in 2025. The Rest of Europe region, including Nordic countries, Eastern Europe, and smaller Western European markets, holds USD 240.0 million in 2025, representing diverse market opportunities with established pharmaceutical and healthcare infrastructure capabilities.

Competitive Landscape of the Cannabigerol Market

The cannabigerol market is characterized by competition among established cannabis companies, specialty extraction companies, and pharmaceutical suppliers focused on delivering high-purity, consistent, and reliable cannabinoid compounds. Companies are investing in extraction technology advancement, quality control enhancement, strategic partnerships, and customer technical support to deliver effective, efficient, and reliable cannabinoid solutions that meet stringent pharmaceutical and healthcare requirements. Quality optimization, purity validation protocols, and supply chain strategies are central to strengthening product portfolios and market presence.

EcoGen Biosciences leads the market with a 14.0% market share, offering comprehensive high-purity CBG products with a focus on quality consistency and therapeutic reliability for pharmaceutical applications. Gencanna provides specialized extraction systems with emphasis on pharmaceutical applications and comprehensive technical support services. KND Labs focuses on advanced cannabinoid technologies and customized pharmaceutical solutions for therapeutic systems serving global markets. Mile High Labs delivers established extraction systems with strong quality control systems and customer service capabilities.

Cannabinoid Creations operates with a focus on bringing innovative cannabinoid technologies to specialized pharmaceutical applications and emerging markets. Folium Biosciences provides comprehensive therapeutic compound portfolios, including advanced cannabinoid services, across multiple pharmaceutical applications and healthcare processes. Creo specializes in customized therapeutic solutions and quality management systems for pharmaceutical systems with emphasis on regulatory compliance. Open Book Extracts provides reliable supply chain solutions and technical expertise to enhance market accessibility and customer access to essential cannabinoid compounds.

Key Players in the Cannabigerol Market

• EcoGen Biosciences, Inc.
• GenCanna Global, Inc.
• KND Labs
• Mile High Labs, Inc.
• Cannabinoid Creations, LLC
• Folium Biosciences, Inc.
• Creo Bioscience
• Open Book Extracts, LLC
• Front Range Biosciences, Inc.
• Medical Marijuana, Inc.
• Pure CBG, Inc.
• Biomedican
• Boulder Botanicals, LLC
• Hemp Synergistics, Inc.
• Chromadex, Inc.

Scope of the Report

Items	Values
Quantitative Units (2025)	USD 890.0 Million
Source	Hemp, Synthetic
Application	Pharmaceuticals, Nutraceuticals, Cosmetics
Form	Isolate, Full Spectrum
Regions Covered	Asia Pacific, North America, Europe, Latin America, Middle East & Africa
Countries Covered	China, USA, Germany, Japan, Canada, South Korea, UK and 40+ countries
Key Companies Profiled	EcoGen Biosciences, Gencanna, KND Labs, Mile High Labs, and Cannabinoid Creations
Additional Attributes	Dollar sales by source and application, regional demand trends, competitive landscape, pharmaceutical provider preferences for specific cannabinoid compounds, integration with specialty healthcare supply chains, innovations in extraction technologies, quality monitoring, and therapeutic optimization

Cannabigerol Market by Segments

• Source :

  • Hemp
  • Synthetic

• Application :

  • Pharmaceuticals
  • Nutraceuticals
  • Cosmetics

• Form :

  • Isolate
  • Full Spectrum

• Region :

  • Asia Pacific

    • China
    • India
    • Japan
    • South Korea
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia Pacific

  • North America

    • United States
    • Canada
    • Mexico

  • Europe

    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Nordic
    • BENELUX
    • Rest of Europe

  • Latin America

    • Brazil
    • Argentina
    • Chile
    • Rest of Latin America

  • Middle East & Africa

    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Other African Countries
    • Rest of Middle East & Africa